Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07118670 · ClinicalTrials.gov registry record · Phase 4
High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes
A Phase 4 study of Proliferative Diabetic Retinopathy (PDR), sponsored by Edward Wood, MD.
- Active
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 3
- Study locations
NCT07118670: Active Phase 4 study of Proliferative Diabetic Retinopathy (PDR), sponsored by Edward Wood, MD.
NCT07118670 is a Phase 4 study of Proliferative Diabetic Retinopathy (PDR) that is active but no longer recruiting, run by Edward Wood, MD. The registered enrollment target is 40 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07118670, a Phase 4 study of Proliferative Diabetic Retinopathy (PDR), is active but no longer recruiting, sponsored by Edward Wood, MD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
Primary Outcome
Proportion of eyes with ≥ 2 step improvement in diabetic retinopathy severity scale (DRSS), as assessed by the central reading center
Conditions Studied
Interventions
- DRUG Aflibercept 8mg
Study Locations (3)
Texas
- Retina Consultants of Texas - Austin Retina Associates - Austin
- Retina Consultants of Texas - Bellaire
- Retina Consultants of Texas - San Antonio - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-12-08 |
| Est. Completion | 2028-04 |
| Phase | Phase 4 |
What the registry record for NCT07118670 still lists
NCT07118670 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (92% lower).
The record links to 1 condition, with Proliferative Diabetic Retinopathy (PDR) appearing as the primary indexed condition, and to 1 intervention - of which Aflibercept 8mg is the first listed.
NCT07118670 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07118670 about?
NCT07118670 is a clinical study titled "High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes". The purpose of this Phase 4 study is to evaluate the safety of aflibercept 8mg in patients with proliferative diabetic retinopathy without center-involved diabetic macular edema.
What is the current status of trial NCT07118670?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2025-12-08. Estimated completion is 2028-04.
What conditions does trial NCT07118670 study?
This clinical trial studies the following conditions: Proliferative Diabetic Retinopathy (PDR).
What interventions are being tested in trial NCT07118670?
The interventions under investigation include: Aflibercept 8mg (DRUG).
Who is sponsoring clinical trial NCT07118670?
This trial is sponsored by Edward Wood, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07118670 being conducted?
This trial has 3 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Proliferative Diabetic Retinopathy (PDR)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07118670's enrollment target sits among peer trials
40 1397th of 2000 higher than 534 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI